Northern Trust
RANI icon

Northern Trust’s Rani Therapeutics RANI Stock Holding History

Northern Trust’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$125K Hold
170,471
– – ﹤0.01% 4056
2025
Q4 		$230K Buy
170,471
+73,466
+76% +$111K ﹤0.01% 3929
2025
Q3 		$48.5K Sell
97,005
-5,906
-6% -$3.08K ﹤0.01% 4288
2025
Q2 		$52.9K Sell
102,911
-1,479
-1% -$1.21K ﹤0.01% 4222
2025
Q1 		$132K Sell
104,390
-1,244
-1% -$1.84K ﹤0.01% 4051
2024
Q4 		$145K Hold
105,634
– – ﹤0.01% 4079
2024
Q3 		$228K Buy
105,634
+70,328
+199% +$202K ﹤0.01% 3839
2024
Q2 		$134K Buy
35,306
+9,318
+36% +$48.3K ﹤0.01% 3976
2024
Q1 		$80.8K Buy
25,988
+6,567
+34% +$22.6K ﹤0.01% 4136
2023
Q4 		$64.5K Hold
19,421
– – ﹤0.01% 4191
2023
Q3 		$42.2K Hold
19,421
– – ﹤0.01% 4205
2023
Q2 		$80K Buy
19,421
+2,305
+13% +$10.7K ﹤0.01% 4095
2023
Q1 		$88.3K Hold
17,116
– – ﹤0.01% 4111
2022
Q4 		$101K Hold
17,116
– – ﹤0.01% 4089
2022
Q3 		$164K Buy
17,116
+5,686
+50% +$60.3K ﹤0.01% 3953
2022
Q2 		$118K Hold
11,430
– – ﹤0.01% 4105
2022
Q1 		$154K Hold
11,430
– – ﹤0.01% 4218
2021
Q4 		$187K Hold
11,430
– – ﹤0.01% 4219
2021
Q3 		$204K Buy
+11,430
New +$198K ﹤0.01% 4170

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Northern Trust's RANI Position: Q1 2026 in Review

Northern Trust held its Rani Therapeutics (RANI) position steady in Q1 2026 at 170,471 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #4056.

Northern Trust first reported a position in RANI in Q3 2021 and has held it in 19 quarters since. The position peaked at $230K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Northern Trust held 170,471 shares of Rani Therapeutics worth $125K as of Q1 2026.
  • Northern Trust left its Rani Therapeutics share count unchanged in Q1 2026.
  • Rani Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4056 holding.
  • Northern Trust first reported a position in Rani Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Northern Trust's Rani Therapeutics position peaked at $230K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.